Methods for reducing cd36 expression
Abstract
The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3 p m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1.
Claims
exact text as granted — not AI-modified1 .- 10 . (canceled)
11 . A method for treating tubular epithelial cell apoptosis in a subject in need thereof comprising administering to the subject an effective amount of an aromatic-cationic peptide having the formula D-Arg-2′6′-Dmt-Lys-Phe-NH 2 or Phe-D-Arg-Phe-Lys-NH 2 or a pharmaceutically acceptable salt thereof.
12 . The method of claim 11 , wherein the peptide has the formula D-Arg-2′6′-Dmt-Lys-Phe-NH 2 .
13 . The method of claim 11 , wherein the peptide has the formula Phe-D-Arg-Phe-Lys-NH 2 .
14 . The method of claim 11 , wherein the subject is a human.
15 . The method of claim 11 , wherein the peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intramuscularly or transdermally.
16 . The method of claim 11 , wherein the tubular epithelial cell apoptosis is associated with unilateral ureteral obstruction.
17 . The method of claim 11 , wherein the method further treats interstitial fibrosis in the subject.
18 . The method of claim 11 , wherein the method further reduces macrophage infiltration in the subject.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.